JP2008500287A5 - - Google Patents

Download PDF

Info

Publication number
JP2008500287A5
JP2008500287A5 JP2007513610A JP2007513610A JP2008500287A5 JP 2008500287 A5 JP2008500287 A5 JP 2008500287A5 JP 2007513610 A JP2007513610 A JP 2007513610A JP 2007513610 A JP2007513610 A JP 2007513610A JP 2008500287 A5 JP2008500287 A5 JP 2008500287A5
Authority
JP
Japan
Prior art keywords
paracetamol
rpm
hydrochloric acid
dosage formulation
usp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007513610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008500287A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2005/000758 external-priority patent/WO2005115344A1/en
Publication of JP2008500287A publication Critical patent/JP2008500287A/ja
Publication of JP2008500287A5 publication Critical patent/JP2008500287A5/ja
Pending legal-status Critical Current

Links

JP2007513610A 2004-05-28 2005-05-27 経口供給系 Pending JP2008500287A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57547704P 2004-05-28 2004-05-28
PCT/AU2005/000758 WO2005115344A1 (en) 2004-05-28 2005-05-27 Oral delivery system

Publications (2)

Publication Number Publication Date
JP2008500287A JP2008500287A (ja) 2008-01-10
JP2008500287A5 true JP2008500287A5 (enExample) 2008-07-17

Family

ID=35450634

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007513610A Pending JP2008500287A (ja) 2004-05-28 2005-05-27 経口供給系

Country Status (6)

Country Link
US (1) US20050276847A1 (enExample)
EP (1) EP1761250A4 (enExample)
JP (1) JP2008500287A (enExample)
AU (1) AU2005247047C1 (enExample)
CA (1) CA2566331C (enExample)
WO (1) WO2005115344A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
EA015336B1 (ru) * 2005-06-03 2011-06-30 Элан Фарма Интернэшнл Лтд. Стабильная композиция с наночастицами ацетаминофена
JP2009517346A (ja) * 2005-11-28 2009-04-30 イメイジノット ピーティーワイ エルティーディー 治療用化合物の経口送達系
GB2443793B (en) * 2006-04-05 2010-12-01 Reckitt Benckiser Healthcare Product, method of manufacture and use
GB0607085D0 (en) 2006-04-07 2006-05-17 Smithkline Beecham Corp Novel compositions
KR20110043655A (ko) * 2008-07-11 2011-04-27 바스프 에스이 모폴로지 변경제로서의 양친매성 단백질
JP6050564B2 (ja) * 2010-03-11 2016-12-21 テイカ製薬株式会社 フィルム状製剤
US20140128415A1 (en) * 2012-05-30 2014-05-08 Paul Daniel Yered Excipient drug composition
WO2014203140A1 (en) * 2013-06-22 2014-12-24 Wockhardt Limited Solid oral pharmaceutical compositions comprising fixed dose combination of acetaminophen, dicyclomine and dextropropoxyphene or salts thereof
US20160331688A1 (en) 2014-01-31 2016-11-17 Shionogi & Co., Ltd. Sustained release formulation
BE1021194B1 (nl) * 2014-07-07 2015-07-14 Nordic Specialty Pharma Bvba Paracetamol tabletten
US11246846B2 (en) * 2017-10-23 2022-02-15 Michael S. Tempesta Trisodium citrate compositions having enhanced uptake across digestive mucosa

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9704524D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Composition
AU3574500A (en) * 1999-03-25 2000-10-16 Yuhan Corporation Rapidly disintegrable tablet for oral administration
GB0114069D0 (en) * 2001-06-08 2001-08-01 Smithkline Beecham Plc Composition
WO2003074029A1 (en) * 2002-03-07 2003-09-12 Vectura Limited Fast melt multiparticulate formulations for oral delivery
WO2004004705A2 (en) * 2002-07-03 2004-01-15 Shannon Biotechnology Ltd Pharmaceutical formulations for preparing drink products
US20040204475A1 (en) * 2003-04-11 2004-10-14 Humphrey Michael John Pharmaceutical combination

Similar Documents

Publication Publication Date Title
JP5285913B2 (ja) 経口投与できる固体の放出改変型医薬投与形
ES2284507T3 (es) Procedimiento de fabricacion de granulos revestidos con sabor enmascarado y de liberacion inmediata del principio activo.
ES2347968T3 (es) Preparacion solida que se disgrega rapidamente.
DK2588086T3 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 4-AMINO-5-FLUORO-3- [6- (4-METHYLPIPERAZIN-1-YL) -1H-BENZIMIDAZOL-2-YL] -1H-QUINOLIN-2-ON-LACTATE MONOHYDRATE
JP4740740B2 (ja) 薬物含有粒子および該粒子を含む固形製剤
RU2008151949A (ru) Фармацевтические лекарственные формы и композиции фенилэфрина для абсорбции в ободочной кишке
JP2017525712A5 (enExample)
JP2006516570A5 (enExample)
JP2006527195A (ja) トリプタンおよびｎｓａｉｄを含む組成物
EP1315478A2 (en) Controlled release formulation of erythromycin or a derivative thereof
JP2007091758A5 (enExample)
JP2012240917A (ja) 製剤化用微粒子とそれを含む製剤
US20040166162A1 (en) Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
JP2008500287A5 (enExample)
CN106456535B (zh) 稳定的孟鲁司特溶液
JP2774135B2 (ja) 固体の急速に崩壊する剤形
JP5208729B2 (ja) 徐放性錠剤の製造方法
JP2005132803A (ja) 胃内滞留固形剤
CA2566331A1 (en) Oral delivery system
JPWO2011121823A1 (ja) 経口投与用粒子状医薬組成物
JP2010120959A5 (enExample)
JP6015116B2 (ja) 錠剤及びその製造方法
EP1512394B1 (en) Universal controlled-release composition comprising chitosan
ITMI992549A1 (it) Nuova composizione
ES2706994T3 (es) Composición farmacéutica de liberación prolongada de administración oral que contiene clorhidrato de hidromorfona